Nuclear medicine FDA approved lutathera.
Ended Purchase Order Awarded Last action
- Contract number
- HT001423P0312
- Awardee
-
Advanced Accelerator Applications USA Inc. UEI JNM4NBNHFE66
- Awarding agency
-
Defense Health Agency
Department of Defense
- Obligated
- $468,068
Award facts
- Contract value 100% obligated
- $468,068.42 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- Contracting staff
- NAICS code
- 325412 Pharmaceutical Preparation Manufacturing
- Set-aside
- No set-aside
- Competition
- Not Competed under SAP · 1 offer Simplified Acquisition
- Pricing
- Firm Fixed Price
- Place of performance
- Bethesda, MD 20889, USA
Award details come from SAM.gov/FPDS.
About this award
The Defense Health Agency, a component of the Department of Defense, awarded a $468,068 firm fixed price purchase order to Advanced Accelerator Applications USA Inc. to deliver FDA-approved Lutathera, a nuclear medicine used in cancer treatment. Performance will take place in Bethesda, Maryland over a three month period concluding at the end of December 2023. No set aside designation or subcontractors were identified. This purchase supports the Defense Health Agency's mission to provide health care services and support to military members, veterans, and their families.
Quick answers
Who was awarded contract HT001423P0312?
HT001423P0312 was awarded to Advanced Accelerator Applications USA Inc. by Defense Health Agency (Department of Defense) on September 30, 2023.
How much is contract HT001423P0312 worth?
The government has obligated $468,068 on HT001423P0312.
Was contract HT001423P0312 competed?
The extent of competition for HT001423P0312 was not competed under sap. The government received 1 offer.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award